Physician profile
David D Powell
NPI 1538153689
$482.90
in general payments reported to CMS, 2019-2025
14 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $30.00 · 2022: $92.57 · 2023: $68.39 · 2024: $56.88 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.65 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $134.38 | 2025 | Trelstar |
| Celgene Corporation | $57.12 | 2023-2024 | Reblozyl |
| Pfizer INC. | $44.86 | 2020-2023 | |
| G1 Therapeutics, INC. | $36.09 | 2022-2023 | Cosela |
| Astrazeneca Pharmaceuticals LP | $26.69 | 2022 | |
| Genentech USA, INC. | $25.66 | 2022 | |
| Janssen Biotech, INC. | $25.31 | 2019 | |
| Astellas Pharma US INC | $24.59 | 2019 | |
| Daiichi Sankyo INC. | $21.26 | 2022 | |
| Puma Biotechnology, INC. | $21.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.02 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2020 | |
| Amgen INC. | $15.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.